GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Unity Biotechnology Inc (NAS:UBX) » Definitions » ROE %

Unity Biotechnology (Unity Biotechnology) ROE % : -18.55% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Unity Biotechnology ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Unity Biotechnology's annualized net income for the quarter that ended in Dec. 2023 was $-5.99 Mil. Unity Biotechnology's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $32.30 Mil. Therefore, Unity Biotechnology's annualized ROE % for the quarter that ended in Dec. 2023 was -18.55%.

The historical rank and industry rank for Unity Biotechnology's ROE % or its related term are showing as below:

UBX' s ROE % Range Over the Past 10 Years
Min: -196.95   Med: -88.73   Max: -58.41
Current: -87.13

During the past 8 years, Unity Biotechnology's highest ROE % was -58.41%. The lowest was -196.95%. And the median was -88.73%.

UBX's ROE % is ranked worse than
71.07% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs UBX: -87.13

Unity Biotechnology ROE % Historical Data

The historical data trend for Unity Biotechnology's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unity Biotechnology ROE % Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -58.41 -92.19 -85.26 -76.90 -94.36

Unity Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.66 -75.77 -90.38 -142.87 -18.55

Competitive Comparison of Unity Biotechnology's ROE %

For the Biotechnology subindustry, Unity Biotechnology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unity Biotechnology's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Unity Biotechnology's ROE % distribution charts can be found below:

* The bar in red indicates where Unity Biotechnology's ROE % falls into.



Unity Biotechnology ROE % Calculation

Unity Biotechnology's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-39.86/( (56.084+28.398)/ 2 )
=-39.86/42.241
=-94.36 %

Unity Biotechnology's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-5.992/( (36.206+28.398)/ 2 )
=-5.992/32.302
=-18.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Unity Biotechnology  (NAS:UBX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-5.992/32.302
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5.992 / 0)*(0 / 67.48)*(67.48 / 32.302)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*2.089
=ROA %*Equity Multiplier
=N/A %*2.089
=-18.55 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-5.992/32.302
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-5.992 / -5.992) * (-5.992 / -28.472) * (-28.472 / 0) * (0 / 67.48) * (67.48 / 32.302)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.2105 * N/A % * 0 * 2.089
=-18.55 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Unity Biotechnology ROE % Related Terms

Thank you for viewing the detailed overview of Unity Biotechnology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Unity Biotechnology (Unity Biotechnology) Business Description

Traded in Other Exchanges
Address
285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Executives
Anirvan Ghosh director, officer: Chief Executive Officer C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael P. Samar director C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Alexander Hieu Nguyen officer: See Remarks C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Nathaniel E David director, officer: President C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Gilmore Neil O'neill director 215 FIRST STREET, CAMBRIDGE MA 02142
Alexander Azoy officer: See Remarks 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Lynne Marie Sullivan officer: See Remarks C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Robert Nelsen director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Graham K Cooper director C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Camille D Samuels director 2463 JACKSON ST., SAN FRANCISCO CA 94115
Kristina Burow director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David L. Lacey director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Dan Marquess officer: Chief Scientific Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005